Ian E. Krop
Impact in
- Oncology top 0.02%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 165
- HER2/EGFR in Cancer Research 115
- Cancer Treatment and Pharmacology 35
- Cancer Immunotherapy and Biomarkers 16
-
- Breast Cancer Treatment Studies 36
- Cancer Genomics and Diagnostics 21
- Co-authors
- Eric P. Winer (63 shared papers)Veronique C Dieras (9 shared papers)Manfred Welslau (3 shared papers)David W. Miles (3 shared papers)Ellie Guardino (4 shared papers)Mark Daniel Pegram (4 shared papers)Sunil Verma (5 shared papers)Luca Gianni (4 shared papers)
- Journals
- Journal of Clinical Oncology (43 papers)Annals of Oncology (33 papers)Clinical Cancer Research (21 papers)Breast Cancer Research and Treatment (14 papers)The Lancet Oncology (10 papers)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Ian E. Krop
251 papers receiving 31.5k citations
Ian E. Krop's Hit Papers
Peers
Comparison fields: 5 of 147
- Oncology 18.9k
- Cancer Research 5.8k
- Pulmonary and Respiratory Medicine 8.4k
- Radiology, Nuclear Medicine and Imaging 5.8k
- Genetics 2.0k
Countries citing papers authored by Ian E. Krop
This map shows the geographic impact of Ian E. Krop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian E. Krop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian E. Krop more than expected).
Fields of papers citing papers by Ian E. Krop
This network shows the impact of papers produced by Ian E. Krop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian E. Krop. The network helps show where Ian E. Krop may publish in the future.
Co-authors
The 25 scholars most cited alongside Ian E. Krop, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 262 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2012 | 3075 |
| 2 | 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) Hit paper breakdown → | 2016 | 1806 |
| 3 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Hit paper breakdown → | 2019 | 1575 |
| 4 | CDK4/6 inhibition triggers anti-tumour immunity Hit paper breakdown → | 2017 | 1178 |
| 5 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2019 | 971 |
| 6 | Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens Hit paper breakdown → | 2017 | 870 |
| 7 | Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy Hit paper breakdown → | 2010 | 636 |
| 8 | Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study Hit paper breakdown → | 2020 | 621 |
| 9 | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2014 | 588 |
| 10 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer Hit paper breakdown → | 2015 | 559 |
| 11 | Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2017 | 537 |
| 12 | Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer Hit paper breakdown → | 2016 | 535 |
| 13 | 2010 | 496 | |
| 14 | 2014 | 465 | |
| 15 | 2017 | 436 | |
| 16 | Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors Hit paper breakdown → | 2016 | 375 |
| 17 | TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes Hit paper breakdown → | 2020 | 366 |
| 18 | 2015 | 337 | |
| 19 | 2017 | 332 | |
| 20 | Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA Hit paper breakdown → | 2014 | 329 |
About Ian E. Krop
Ian E. Krop is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 262 papers that have together received 32.3k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (115 papers), Breast Cancer Treatment Studies (36 papers), Cancer Treatment and Pharmacology (35 papers), Monoclonal and Polyclonal Antibodies Research (30 papers), Advanced Breast Cancer Therapies (22 papers), Cancer Genomics and Diagnostics (21 papers), Brain Metastases and Treatment (19 papers) and Cancer Immunotherapy and Biomarkers (16 papers). The work is most often cited by research in Oncology (18.9k citations), Cancer Research (5.8k citations), Pulmonary and Respiratory Medicine (8.4k citations), Radiology, Nuclear Medicine and Imaging (5.8k citations) and Genetics (2.0k citations). Ian E. Krop has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Eric P. Winer, Veronique C Dieras, Manfred Welslau, David W. Miles, Ellie Guardino, Mark Daniel Pegram, Sunil Verma, Luca Gianni, Kim T. Blackwell and Sara Tolaney. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, Breast Cancer Research and Treatment and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.